Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2021 May 27

PMID 34042995

Citations 27

Authors

Jun Du

Dandan Yu

Xinle Han

Lijun Zhu

Zoufang Huang

Affiliations

Soon will be listed here.

Abstract

Importance: Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), but whether allogeneic HSCT or autologous HSCT is more beneficial is unknown.

Objective: To compare the effectiveness and safety of allogeneic HSCT vs autologous HSCT in patients with R/R-PTCL.

Data Sources: A systematic search of the PubMed, Embase, the Cochrane Central Register of Controlled Trials, Wanfang, and China National Knowledge Infrastructure databases with the search items refractory or relapsed peripheral T-cell lymphoma, ASCT/autologous stem-cell transplantation, allo-HSCT/allogeneic stem-cell transplantation, therapeutic effect, and treatment was conducted for articles published from January 12, 2001, to October 1, 2020.

Study Selection: After duplicate and irrelevant publications were discarded, 329 were ineligible according to the inclusion (clinical trials or retrospective studies with >10 samples) and exclusion criteria (articles without overall survival [OS], progression-free survival [PFS], and transplantation-related mortality [TRM]). Thirty trials were included in the meta-analysis. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.

Data Extraction And Synthesis: Data on study design, individual characteristics, and outcomes were extracted. All statistics were pooled by applying a random-effects model.

Main Outcomes And Measures: The prespecified main outcomes were OS, PFS, and TRM.

Results: Of 6548 articles, data extracted from the 30 studies (including 880 patients who underwent allogeneic HSCT and 885 who underwent autologous HSCT) were included in this meta-analysis. In the allogeneic HSCT group, a 3-year OS of 50% (95% CI, 41%-60%) and PFS of 42% (95% CI, 35%-51%), a 5-year OS of 54% (95% CI, 47%-62%) and PFS of 48% (95% CI, 40%-56%), and a 3-year TRM of 32% (95% CI, 27%-37%) were observed. In the autologous HSCT group, a 3-year OS of 55% (95% CI, 48%-64%) and PFS of 41% (95% CI, 33%-51%), a 5-year OS of 53% (95% CI, 44%-64%) and PFS of 40% (95% CI, 24%-58%), and a 3-year TRM of 7% (95% CI, 2%-23%) were observed.

Conclusions And Relevance: In this systematic review and meta-analysis, OS and PFS were similar in the allogeneic HSCT and autologous HSCT groups; however, allogeneic HSCT was associated with specific survival benefits among patients with R/R-PTCL.

Citing Articles

Acceptability and feasibility of acceptance and commitment therapy for improving outcomes in hematopoietic stem cell transplant.

Merwin R, Smith P, Riley J, Infield J, OConnell C, Mayo D PLoS One. 2025; 20(3):e0319339.

PMID: 40053539 PMC: 11888137. DOI: 10.1371/journal.pone.0319339.

Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy.

Kim H, Chung H, Kook H, Kim S, Kim Y, Cho H Blood Res. 2025; 60(1):12.

PMID: 39928273 PMC: 11811309. DOI: 10.1007/s44313-025-00060-y.

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.

Tian L, Liu C, Zheng S, Shi H, Wei F, Jiang W J Transl Med. 2025; 23(1):82.

PMID: 39825361 PMC: 11748609. DOI: 10.1186/s12967-025-06089-y.

[The efficacy and safety of thioamide in maintenance therapy for peripheral T-cell lymphoma].

Yin H, Liang J, Wu J, Li Y, Zhang X, Kong Y Zhonghua Xue Ye Xue Za Zhi. 2025; 45(12):1091-1097.

PMID: 39765349 PMC: 11886691. DOI: 10.3760/cma.j.cn121090-20240630-00238.

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.

Gao Y, Huang Y, Zhang Q, Yang H, Li Y, Li Y Cancer. 2025; 131(1):e35672.

PMID: 39748491 PMC: 11695808. DOI: 10.1002/cncr.35672.

References

Gu Z, Wang L, Wang Q, Li H, Bo J, Wang S . Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. Ann Hematol. 2018; 98(5):1237-1247. DOI: 10.1007/s00277-018-3559-3. View

Chen A, McMillan A, Negrin R, Horning S, Laport G . Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008; 14(7):741-7. PMC: 2980839. DOI: 10.1016/j.bbmt.2008.04.004. View

Jacobsen E, Kim H, Ho V, Cutler C, Koreth J, Fisher D . A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011; 22(7):1608-1613. PMC: 3121969. DOI: 10.1093/annonc/mdq698. View

Le Gouill S, Milpied N, Buzyn A, Peffault de Latour R, Vernant J, Mohty M . Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008; 26(14):2264-71. DOI: 10.1200/JCO.2007.14.1366. View

Wulf G, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B . Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2005; 36(3):271-3. DOI: 10.1038/sj.bmt.1705036. View

Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F . Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2011; 26(3):520-6. DOI: 10.1038/leu.2011.240. View

Kewalramani T, Zelenetz A, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S . Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006; 134(2):202-7. DOI: 10.1111/j.1365-2141.2006.06164.x. View

Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M . Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2018; 54(6):877-884. DOI: 10.1038/s41409-018-0360-9. View

Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M . Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004; 22(11):2172-6. DOI: 10.1200/JCO.2004.12.050. View

10.

Song K, Mollee P, Keating A, Crump M . Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003; 120(6):978-85. DOI: 10.1046/j.1365-2141.2003.04203.x. View

11.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

12.

Wei J, Xu J, Cao Y, Zhou J, Zhang Y . Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis. Acta Haematol. 2014; 133(2):136-44. DOI: 10.1159/000358579. View

13.

Huang H, Jiang Y, Wang Q, Guo L, Jin Z, Fu Z . Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center. Biol Blood Marrow Transplant. 2017; 23(8):1393-1397. DOI: 10.1016/j.bbmt.2017.04.021. View

14.

Foster C, Kuruvilla J . Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Res. 2020; 9. PMC: 7475955. DOI: 10.12688/f1000research.22257.1. View

15.

Zain J, Palmer J, Delioukina M, Thomas S, Tsai N, Nademanee A . Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma. 2011; 52(8):1463-73. PMC: 3441144. DOI: 10.3109/10428194.2011.574754. View

16.

Domingo-Domenech E, Boumendil A, Climent F, Sengeloev H, Wahlin B, Wattad W . Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplant. 2019; 55(4):796-803. DOI: 10.1038/s41409-019-0734-7. View

17.

Kim M, Kim S, Lee S, Sym S, Lee D, Jang S . High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol. 2007; 86(6):435-42. DOI: 10.1007/s00277-007-0254-1. View

18.

McIlroy G, Barmayehvar B, Kamarajah S, George L, Gondal A, Malladi R . Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma. Eur J Haematol. 2020; 105(4):514-516. DOI: 10.1111/ejh.13465. View

19.

Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-30. DOI: 10.1200/JCO.2008.16.4558. View

20.

Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A . Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014; 28(9):1885-91. DOI: 10.1038/leu.2014.79. View